Talazoparib
Talazoparib is a pharmaceutical drug with 83 clinical trials. Currently 28 active trials ongoing. Historical success rate of 72.1%.
Success Metrics
Based on 31 completed trials
Phase Distribution
Phase Distribution
38
Early Stage
38
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
64.6%
31 of 48 finished
35.4%
17 ended early
28
trials recruiting
83
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Clinical Trials (83)
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 83